| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4996335 (Pediatric) | BAUSCH AND LOMB | Soft steroids having anti-inflammatory activity |
Sep, 2012
(11 years ago) | |
| US5747061 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
| US5540930 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
|
US5747061 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
|
US5540930 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
Alrex is owned by Bausch And Lomb.
Alrex contains Loteprednol Etabonate.
Alrex has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Alrex are:
- US4996335*PED
- US5747061
- US5540930
- US5747061*PED
- US5540930*PED
Alrex was authorised for market use on 09 March, 1998.
Alrex is available in suspension/drops;ophthalmic dosage forms.
Alrex can be used as alrex ophthalmic suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis..
The generics of Alrex are possible to be released after 25 April, 2014.
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 09 March, 1998
Treatment: Alrex ophthalmic suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
Dosage: SUSPENSION/DROPS;OPHTHALMIC
ALREX family patents
